Trending
- Libya’s oil sector just signed its biggest foreign deals in a generation
- African trade is growing despite the obstacles
- Why global capital is betting big on Africa’s digital promise
- Kenya posts stronger-than-expected Q1 growth at 5.3% on manufacturing rebound, tourism boom
- China’s new investment rules are about guardrails, not closed doors
- Zanzibar optimistic economic growth will hit 7.5% on tourism boom
- Kenya defies economic shocks to post record $22 billion in tax collections
- Forget South Africa: East Africa now rules in banking industry returns
Investing
Businesses are expanding across borders, new trade corridors are emerging, and regional ambition remains strong, but liquidity, payments and execution challenges continue to shape…
East Africa’s Kenya and Tanzania are among the strongest value…
In July, Kenya’s markets regulator licensed Shariah-compliant REITs, ESG-aligned advisors,…
A report by Cytonn Investments has found that Kenya’s hospitality sector has continued to show…
Importance of Green Finance in Africa The role of Green Bonds to drive infrastructure development…
mRNA-1644 utilizes Moderna’s messenger RNA (mRNA) technology to deliver a specific class of B cells needed to develop broadly neutralizing antibodies (bnAbs) to fight HIV infection. Inducing bnAbs is considered the primary goal of an HIV vaccine, and this requires B-cell activation.
The primary trial endpoints are safety and immunogenicity. The IAVI-sponsored clinical trial, IAVI G003, will test the safety and efficacy of vaccination with the HIV immunogen eOD-GT8 60mer, delivered via Moderna’s mRNA platform. eOD-GT8 60mer was developed by IAVI and Scripps Research teams and was initially tested in phase 1 clinical trial IAVI G001.
According to Contagion Live, IAVI G003 is expected to enroll 18 healthy, HIV-negative adults. The participants will receive 2 doses of eOD-GT8 60mer mRNA, which contains a portion of the viral sequence but cannot cause HIV infection. They will be monitored for safety for 6 months after their second dose, and their immune responses will be examined in molecular detail to evaluate whether the target was achieved.
The Africa Green Hydrogen Alliance targets accelerating the transition from fossil fuels overreliance that has…
The current president of Tanzania is actively pursuing a foreign policy distinct from the one…
Copper production is set to resume at Alaska Mine in Chinhoyi after a US$6 million capital injection by Chinese investors in partnership with the Zimbabwe Mining Development Corporation (ZMDC). The total capital injection required is US$12 million and so far, a Chinese investor, Grand Sanyuan Copper Resources has poured in half the amount.
As far as June 10, 2021, ZBC News said the majority of the funds will be channelled towards the construction and refurbishment of a flotation plant, a smelter, and an electrolysis refinery, with an environmental impact assessment completed.
The Alaska Copper smelting plant has been closed since 2000, but has now been resuscitated and is expected to be fully operational by July this year with a target to produce 300 tonnes of copper per day.
